RATIONALE: Monoclonal antibodies, such as alemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. PURPOSE: This phase II trial is studying how well giving alemtuzumab by injection works in treating patients with advanced chronic lymphocytic leukemia that did not respond to previous fludarabine.
OBJECTIVES: * Compare the safety and efficacy of subcutaneous alemtuzumab vs intravenous alemtuzumab in patients with fludarabine-refractory advanced chronic lymphocytic leukemia. * Determine the response in patients with high-risk genetic abnormalities (unmutated immunoglobulin variable heavy-chain \[IgVH\] status, del \[17p\], del \[11q\]) treated with subcutaneous alemtuzumab after progression on fludarabine. OUTLINE: This is a multicenter study. Patients receive alemtuzumab IV once, followed 1 week later by alemtuzumab subcutaneously once weekly for up to 12 weeks. PROJECTED ACCRUAL: A total of 100 patients will be accrued for this study.
Study Type
INTERVENTIONAL
Purpose
TREATMENT
Masking
NONE
Safety and efficacy
Response
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Allgemeines Krankenhaus der Stadt Wien
Vienna, Austria
Gemeinschaftspraxis Fuer Innere Medizin, Haematologie Und Internistische Onkologie
Ansbach, Germany
Specialist Practice for Oncology
Aschaffenburg, Germany
Humaine - Clinic
Bad Saarow, Germany
Haematolo-Onkologische Schwerpunktpraxis - Berlin
Berlin, Germany
Robert Roessle Comprehensive Cancer Center at University of Berlin - Charite Campus Buch
Berlin, Germany
Hospital Kuchwald Chemnitz
Chemnitz, Germany
Universitaetsklinikum Essen
Essen, Germany
Staedtische Kliniken Esslingen
Esslingen am Neckar, Germany
Krankenhaus Nordwest
Frankfurt, Germany
...and 25 more locations